Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jul;33(7):1203-14.
doi: 10.1016/j.neurobiolaging.2010.10.019. Epub 2010 Dec 14.

Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance

Affiliations

Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance

Michael Ewers et al. Neurobiol Aging. 2012 Jul.

Abstract

The current study tested the accuracy of primary MRI and cerebrospinal fluid (CSF) biomarker candidates and neuropsychological tests for predicting the conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD) dementia. In a cross-validation paradigm, predictor models were estimated in the training set of AD (N = 81) and elderly control subjects (N = 101). A combination of CSF t-tau/Aβ(1-4) ratio and MRI biomarkers or neuropsychological tests (free recall and trail making test B (TMT-B)) showed the best statistical fit in the AD vs. HC comparison, reaching a classification accuracy of up to 64% when applied to the prediction of MCI conversion (3.3-year observation interval, mean = 2.3 years). However, several single-predictor models showed a predictive accuracy of MCI conversion comparable to that of any multipredictor model. The best single predictors were right entorhinal cortex (prediction accuracy = 68.5% (95% CI (59.5, 77.4))) and TMT-B test (prediction accuracy 64.6% (95% CI (55.5, 73.4%))). In conclusion, short-term conversion to AD is predicted by single marker models to a comparable degree as by multimarker models in amnestic MCI subjects.

PubMed Disclaimer

Conflict of interest statement

None of the other authors have a conflict of interest to disclose.

Figures

Fig. 1
Fig. 1
Flow chart of number of patients undergoing the test under evaluation (index test) and the reference test. HCV, Hippocampus volume; ERC, Entorhinal cortical thickness.
Fig. 2
Fig. 2
Distribution of MCI-AD converters (green triangles) vs. MCI nonAD (red circles) as a function of left hippocampus volume (ln) and CSF tau/Aβ1-42 ratio (A) and for the entorhinal cortex (mm3) vs. CSF tau/Aβ1-42 ratio (B). The lines show the risk zones for classification as MCI converters or MCI nonconverters. The risk of MCI conversion associated with the left hippocampus volume (A) or left entorhinal cortical thickness (B) is labeled as percentages on each line. The arrow points in the direction of risk increase associated with a decrease in the MRI measures (inset in A and B). Note that an increase in the CSF tau/Aβ1-42 ratio as indicated by the slope of the lines, but a decrease in left hippocampus volume (A) or left entorhinal cortical thickness (B) indicated by the height of the lines is associated with an increased risk of MCI-AD conversion.
Fig. 3
Fig. 3
Bootstrapped mean of the total overall classification accuracy and 95% CI for the 24 rank ordered models of highest CAC each of 1-, 2-, 3-, and 4-predictor models for the classification of MCI conversion within a 2-year interval. For identification of models see supplementary Table 1, where the models are identified by their corresponding rank.

References

    1. Arbuthnott K, Frank J. Trail making test, part B as a measure of executive control: validation using a set-switching paradigm. J Clin Exp Neuropsychol. 2000;22(4):518–528. - PubMed
    1. Backman L, Jones S, Berger AK, Laukka EJ, Small BJ. Cognitive impairment in preclinical Alzheimer's disease: a meta-analysis. Neuropsychology. 2005;19:520–531. - PubMed
    1. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol. 2003;2:605–613. - PubMed
    1. Bouwman FH, Schoonenboom SN, van der Flier WM, van Elk EJ, Kok A, Barkhof F, Blankenstein MA, Scheltens P. CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiol Aging. 2007;28:1070–4. - PubMed
    1. Brys M, Glodzik L, Mosconi L, Switalski R, De Santi S, Pirraglia E, Rich K, Kim BC, Mehta P, Zinkowski R, Pratico D, Wallin A, Zetterberg H, Tsui WH, Rusinek H, Blennow K, de Leon MJ. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease. J Alzheimers Dis. 2009a;16:351–362. - PMC - PubMed

Publication types

MeSH terms